Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...
pharmaphorum4d
Sage rejects Biogen takeover and launches review
The board of Sage Therapeutics unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company. That's not surprising – Sage filed a ...
Seeking Alpha5d
Key deals this week: Molson Coors Beverage, Emerson Electric, Sage Therapeutics and more
Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Diversified Energy (OTCQX:DEC) +2.6% pre-market ...
pharmaphorum4d
Biogen offers to buy out wilting Sage for $442 million
Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...